221 related articles for article (PubMed ID: 33496367)
1. A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19.
Geanon D; Lee B; Gonzalez-Kozlova E; Kelly G; Handler D; Upadhyaya B; Leech J; De Real RM; Herbinet M; Magen A; Del Valle D; Charney A; Kim-Schulze S; Gnjatic S; Merad M; Rahman AH
Cytometry A; 2021 May; 99(5):446-461. PubMed ID: 33496367
[TBL] [Abstract][Full Text] [Related]
2. A Streamlined CyTOF Workflow To Facilitate Standardized Multi-Site Immune Profiling of COVID-19 Patients.
Geanon D; Lee B; Kelly G; Handler D; Upadhyaya B; Leech J; Herbinet M; Del Valle D; Gnjatic S; Kim-Schulze S; Merad M; Rahman A
medRxiv; 2020 Jun; ():. PubMed ID: 32607524
[TBL] [Abstract][Full Text] [Related]
3. Customizing Maxpar Direct Immune Profiling Assay with Additional Surface Marker and Intracellular Cytokine Staining Workflows for Expanded Mass Cytometry Panels.
Petes C; Li SKH; Mujib S; Poulin MM; Saederup N; Quong AA; Loh C
Methods Mol Biol; 2022; 2386():129-145. PubMed ID: 34766269
[TBL] [Abstract][Full Text] [Related]
4. Multi-site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis system.
Bagwell CB; Hunsberger B; Hill B; Herbert D; Bray C; Selvanantham T; Li S; Villasboas JC; Pavelko K; Strausbauch M; Rahman A; Kelly G; Asgharzadeh S; Gomez-Cabrero A; Behbehani G; Chang H; Lyberger J; Montgomery R; Zhao Y; Inokuma M; Goldberger O; Stelzer G
Cytometry B Clin Cytom; 2020 Mar; 98(2):146-160. PubMed ID: 31758746
[TBL] [Abstract][Full Text] [Related]
5. CyTOF
Iyer A; Hamers AAJ; Pillai AB
Front Immunol; 2022; 13():815828. PubMed ID: 35493491
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance.
Zhou D; Zhao S; He K; Liu Q; Zhang F; Pu Z; Xiao L; Zhang L; Chen S; Qian X; Wu X; Shen Y; Yu L; Zhang H; Jin J; Xu M; Wang X; Zhu D; Xie Z; Xu X
BMC Infect Dis; 2024 Jun; 24(1):567. PubMed ID: 38844850
[TBL] [Abstract][Full Text] [Related]
7. Enumeration of major peripheral blood leukocyte populations for multicenter clinical trials using a whole blood phenotyping assay.
Hensley TR; Easter AB; Gerdts SE; De Rosa SC; Heit A; McElrath MJ; Andersen-Nissen E
J Vis Exp; 2012 Sep; (67):e4302. PubMed ID: 23007739
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotyping of Human Peripheral Blood Mononuclear Cells by Mass Cytometry.
Heck S; Bishop CJ; Ellis RJ
Methods Mol Biol; 2019; 1979():285-303. PubMed ID: 31028645
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study.
;
Sci Immunol; 2021 Aug; 6(62):. PubMed ID: 34376480
[TBL] [Abstract][Full Text] [Related]
10. Mass Cytometry Analysis of T-Helper Cells.
Subrahmanyam PB; Maecker HT
Methods Mol Biol; 2021; 2285():49-63. PubMed ID: 33928542
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Kang CK; Kim M; Lee S; Kim G; Choe PG; Park WB; Kim NJ; Lee CH; Kim IS; Jung K; Lee DS; Shin HM; Kim HR; Oh MD
J Infect Dis; 2021 Jul; 224(1):39-48. PubMed ID: 33755725
[TBL] [Abstract][Full Text] [Related]
12. Automated flow cytometry enables high performance point-of-care analysis of leukocyte phenotypes.
Spijkerman R; Hesselink L; Hellebrekers P; Vrisekoop N; Hietbrink F; Leenen LPH; Koenderman L
J Immunol Methods; 2019 Nov; 474():112646. PubMed ID: 31419409
[TBL] [Abstract][Full Text] [Related]
13. T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19.
Zenarruzabeitia O; Astarloa-Pando G; Terrén I; Orrantia A; Pérez-Garay R; Seijas-Betolaza I; Nieto-Arana J; Imaz-Ayo N; Pérez-Fernández S; Arana-Arri E; Borrego F
Front Immunol; 2021; 12():655934. PubMed ID: 33777054
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Study Investigating Immune Checkpoint Molecule and CD39 Expression on Peripheral Blood Cells for the Prognostication of COVID-19 Severity and Mortality.
Gambichler T; Rüth J; Goesmann S; Höxtermann S; Skrygan M; Susok L; Becker JC; Overheu O; Schmidt W; Reinacher-Schick A
Viruses; 2024 May; 16(5):. PubMed ID: 38793691
[TBL] [Abstract][Full Text] [Related]
15. A Method of Assessment of Human Natural Killer Cell Phenotype and Function in Whole Blood.
Market M; Tennakoon G; Ng J; Scaffidi M; de Souza CT; Kennedy MA; Auer RC
Front Immunol; 2020; 11():963. PubMed ID: 32508837
[TBL] [Abstract][Full Text] [Related]
16. Broad Immune Monitoring and Profiling of T Cell Subsets with Mass Cytometry.
Brodie TM; Tosevski V
Methods Mol Biol; 2018; 1745():67-82. PubMed ID: 29476463
[TBL] [Abstract][Full Text] [Related]
17. High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples.
Thrash EM; Kleinsteuber K; Hathaway ES; Nazzaro M; Haas E; Hodi FS; Severgnini M
STAR Protoc; 2020 Sep; 1(2):100055. PubMed ID: 33111099
[TBL] [Abstract][Full Text] [Related]
18. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.
Kreutmair S; Unger S; Núñez NG; Ingelfinger F; Alberti C; De Feo D; Krishnarajah S; Kauffmann M; Friebel E; Babaei S; Gaborit B; Lutz M; Jurado NP; Malek NP; Goepel S; Rosenberger P; Häberle HA; Ayoub I; Al-Hajj S; Nilsson J; Claassen M; Liblau R; Martin-Blondel G; Bitzer M; Roquilly A; Becher B
Immunity; 2021 Jul; 54(7):1578-1593.e5. PubMed ID: 34051147
[TBL] [Abstract][Full Text] [Related]
19. Mass cytometry for the multiplexed quantification and characterization of target expression on circulating cells in whole blood.
Stevens CR; Atkuri K; Menard DL; King LE; Neubert H; Goihberg P
Cytometry A; 2023 Aug; 103(8):631-645. PubMed ID: 36966446
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of six SARS-CoV-2 serology assays: Diagnostic performance and antibody dynamics in a cohort of hospitalized patients for moderate to critical COVID-19.
Chamkhi S; Dhaouadi T; Sfar I; Mokni S; Jebri A; Mansouri D; Ghedira S; Ben Jemia E; Ben Boujemaa S; Houissa M; Aouina H; Ben Abdallah T; Gorgi Y
Int J Immunopathol Pharmacol; 2022; 36():20587384211073232. PubMed ID: 35113728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
